Additional file 1: of Assessment of adverse events via a telephone consultation service for cancer patients receiving ambulatory chemotherapy

Figure S1. A) Common adverse events reported during consultation. B) Chemotherapy regimens of patients using the telephone consultation service. AC; adriamycin + cyclophosphamide, CBDCA; carboplatin, PTX; paclitaxel, GEM; gemcitabine, CEF; cyclophosphamide + epirubicine + 5-FU, CDDP; cisplatin, BV; bevacizumab.